All In Biotech

Drug Trial Radar · NCT06202378

Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke

A Multicenter, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Oct 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

270

Actual

Start

Dec 29, 2023

Primary completion

Nov 26, 2024

Study completion Dec 16, 2024

Sponsor

Sponsor type
Industry
Collaborators
Beijing Tiantan Hospital
First posted
Jan 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine the safety and efficacy of SHPL-49 intravenous infusion for 7 consecutive days in the treatment of acute ischemic stroke subjects.

Conditions

  • Acute Ischemic Stroke

Interventions

  • 3 ampoules of SHPL-49 InjectionDrug

    3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7 days.

  • 6 ampoules of SHPL-49 InjectionDrug

    6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7 days.

  • 0.9% Sodium Chloride InjectionDrug

    100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (mRS), with scores of 0-1 at Day 90Time frame: 90±7 days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hosptial,Capital Medical University

    Beijing, Beijing Municipality, China

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China

  • Hengshui People's Hospital

    Hengshui, Hebei, China

  • Tangshan Workers' Hospital

    Tangshan, Hebei, China

  • Nanshi Hospital of Nanyang

    Nanyang, Henan, China

  • General Hospital of Pingmei Shenma Group

    Pingdingshan, Henan, China

  • Keshiketeng Banner Traditional Chinese Medicine and Mongolian Medicine Hospital

    Chifeng, Inner Mongolia, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Beipiao Central Hospital

    Beipiao, Liaoning, China

  • Shenyang Medical College Affiliated Central Hospital

    Shenyang, Liaoning, China

  • The First People's Hospital of Shenyang

    Shenyang, Liaoning, China

  • Linyi People's Hospital

    Linyi, Shandong, China

  • The First People's Hospital of Tancheng

    Linyi, Shandong, China

  • Sinopharm Tongmei General Hospital

    Datong, Shanxi, China

  • Linfen Central Hospital

    Linfen, Shanxi, China

  • Linfen People's Hospital

    Linfen, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.